Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Brainsway Ltd(BWAY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BWAY
09/25/2026: BWAY (3-star) is currently NOT-A-BUY. Pass it for now.
Brainsway Ltd is a specialized medical technology company that provides non-invasive Deep TMS systems to treat mental health disorders such as depression and OCD. Its core strength lies in its patented H-Coil technology, which enables deeper brain stimulation compared to standard TMS devices, giving it a unique position in the clinical market. The primary growth story centers on increasing the installed base of its systems and securing additional FDA clearances for broader psychiatric conditions. However, the company faces significant competition from well-capitalized players and remains sensitive to changes in healthcare reimbursement. It is best suited for growth-oriented investors who can tolerate the volatility associated with medical device companies.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in the high-growth mental health technology sector with a scalable revenue model. |
| Momentum investor | Mixed fit | Momentum participation is conditional on positive clinical data releases and sustained revenue growth trends. |
| Value investor | Weak fit | The company is currently prioritized for growth and R&D rather than near-term earnings yield or deep value metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital into expansion. |
| Low-risk investor | Weak fit | Medical device stocks with limited profitability carry higher volatility and risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap health technology stocks can experience significant price swings based on clinical news. |
| Valuation risk | Medium / high | The stock's valuation is highly sensitive to growth expectations and long-term profitability targets. |
| Competition risk (TMS market) | Medium | Established players like Neuronetics provide strong competition for market share in psychiatric clinics. |
| Business quality | Medium | The company has a strong, unique product, but it is still working toward consistent, scalable profitability. |
| Dividend income | Low / none | Investors should expect zero income contribution from this equity. |
| Execution risk | Medium | Successfully expanding the installed base and securing favorable insurance coverage is critical for financial performance. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 77.35% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 531.58M USD | Price to earnings Ratio 57.43 | 1Y Target Price 19.27 |
Price to earnings Ratio 57.43 | 1Y Target Price 19.27 | ||
Volume (30-day avg) 86.4K shares | Beta 0.08 | 52 Weeks Range 7.13 - 17.40 | Updated Date 09/24/2026 |
52 Weeks Range 7.13 - 17.40 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.23 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Deep TMS Systems | Direct sales and leasing of the hardware platform to clinics. | Revenue is generated by placing machines in clinics and hospitals. |
| Consumables and Services | Proprietary helmets and maintenance contracts. | This creates a recurring revenue stream as more patients get treated. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 57.43 | Forward PE 17.92 | Enterprise Value 497.90M | Price to Sales(TTM) 8.76 |
Enterprise Value 497.90M | Price to Sales(TTM) 8.76 | ||
Enterprise Value to Revenue 8.2 | Enterprise Value to EBITDA 41.85 | Shares Outstanding 40.24M | Shares Floating 23.25M |
Shares Outstanding 40.24M | Shares Floating 23.25M | ||
Percent Insiders 2.54 | Percent Institutions 32.48 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Brainsway Ltd
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 1999-10-06 | CEO - | ||
Sector Healthcare | Industry Medical Devices | Full time employees 129 | Website https://www.brainsway.com |
Full time employees 129 | Website https://www.brainsway.com | ||
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.